For the year ending 2025-12-31, COCH made $241K in revenue. -$28,662K in net income. Net profit margin of -11892.95%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Net revenues | 241 | 225 | ||
| Cost of goods sold | 874 | 742 | ||
| Research and development | 12,486 | 10,179 | ||
| Sales and marketing | 1,220 | 1,734 | ||
| General and administrative | 7,931 | 6,826 | ||
| Total costs and operating expenses | 22,511 | 19,481 | ||
| Change in fair value of forward purchase agreement put option liability | - | 103 | ||
| Operating loss | -22,270 | -19,256 | ||
| Change in fair value of forward purchase agreement warrant liability | -534 | -411 | ||
| Change in fair value of forward purchase agreement warrant liability due to extension | 24 | - | ||
| Loss on offering and change in fair value of private warrant liability | 494 | - | ||
| Change in fair value of publicly traded warrant liability | -111 | 330 | ||
| Interest expense, related party | 1,590 | 816 | ||
| Change in fair value of forward purchase agreement warrant liability due to modification | - | 881 | ||
| Other expense, net | -23 | -26 | ||
| Total other income (expense), net | -1,486 | -1,539 | ||
| Net loss | -23,756 | -20,795 | ||
| Cumulative preferred dividends | 4,906 | 5,521 | ||
| Induced conversion of series a preferred stock into class a common stock | - | 1,162 | ||
| Deemed dividend on waiver of restriction on class a common stock | - | 495 | ||
| Net loss attributable to common stockholders, basic | -28,662 | -27,973 | ||
| Basic EPS | -1.23 | -1.49 | ||
| Diluted EPS | -1.23 | -1.49 | ||
| Basic Average Shares | 23,259,598 | 18,790,448 | ||
| Diluted Average Shares | 23,259,598 | 18,790,448 | ||
Envoy Medical, Inc. (COCH)
Envoy Medical, Inc. (COCH)